Literature DB >> 9620997

Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry.

S M Owen1, D Ellenberger, M Rayfield, S Wiktor, P Michel, M H Grieco, F Gao, B H Hahn, R B Lal.   

Abstract

Several members of the seven-transmembrane chemokine receptor family have been shown to serve, with CD4, as coreceptors for entry by human immunodeficiency virus type 1 (HIV-1). While coreceptor usage by HIV-1 primary isolates has been studied by several groups, there is only limited information available concerning coreceptor usage by primary HIV-2 isolates. In this study, we have analyzed coreceptor usage of 15 primary HIV-2 isolates, using lymphocytes from a donor with nonfunctional CCR5 (CCR5 -/-; homozygous 32-bp deletion). Based on the infections of PBMCs, seven of these primary isolates had an absolute requirement for CCR5 expression, whereas the remaining eight exhibited a broader coreceptor usage. All CCR5-requiring isolates were non-syncytium inducing, whereas isolates utilizing multiple coreceptors were syncytium inducing. Blocking experiments using known ligands for chemokine receptors provided indirect evidence for additional coreceptor utilization by primary HIV-2 isolates. Analysis of GHOST4 cell lines expressing various chemokine receptors (CCR1, CCR2b, CCR3, CCR4, CCR5, CXCR4, BONZO, and BOB) further defined specific coreceptor usage of primary HIV-2 isolates. The receptors used included CXCR4, CCR1-5, and the recently described receptors BONZO and BOB. However, the efficiency at which the coreceptors were utilized varied greatly among the various isolates. Analysis of V3 envelope sequences revealed no specific motif that correlated with coreceptor usage. Our data demonstrate that primary HIV-2 isolates are capable of using a broad range of coreceptors for productive infection in vitro. Additionally, our data suggest that expanded coreceptor usage by HIV-2 may correlate with disease progression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620997      PMCID: PMC110175     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

Review 1.  HIV entry and tropism: the chemokine receptor connection.

Authors:  E A Berger
Journal:  AIDS       Date:  1997       Impact factor: 4.177

2.  Assays for retroviral reverse transcriptase.

Authors:  A Telesnitsky; S Blain; S P Goff
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

3.  A prospective study of vertical transmission of HIV-2 in Bissau, Guinea-Bissau.

Authors:  P A Andreasson; F Dias; A Nauclér; S Andersson; G Biberfeld
Journal:  AIDS       Date:  1993-07       Impact factor: 4.177

4.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; S K Arya; R C Gallo; P Lusso
Journal:  Science       Date:  1995-12-15       Impact factor: 47.728

5.  Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology.

Authors:  F Gao; L Yue; D L Robertson; S C Hill; H Hui; R J Biggar; A E Neequaye; T M Whelan; D D Ho; G M Shaw
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

6.  Recombination in AIDS viruses.

Authors:  D L Robertson; B H Hahn; P M Sharp
Journal:  J Mol Evol       Date:  1995-03       Impact factor: 2.395

7.  Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic.

Authors:  K M De Cock; G Adjorlolo; E Ekpini; T Sibailly; J Kouadio; M Maran; K Brattegaard; K M Vetter; R Doorly; H D Gayle
Journal:  JAMA       Date:  1993-11-03       Impact factor: 56.272

Review 8.  Population migration and the spread of types 1 and 2 human immunodeficiency viruses.

Authors:  T C Quinn
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

9.  Slower heterosexual spread of HIV-2 than HIV-1.

Authors:  P J Kanki; K U Travers; S MBoup; C C Hsieh; R G Marlink; A Gueye-NDiaye; T Siby; I Thior; M Hernandez-Avila; J L Sankalé
Journal:  Lancet       Date:  1994-04-16       Impact factor: 79.321

10.  Dual tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus type 1 and 2 isolates.

Authors:  A Valentin; J Albert; E M Fenyö; B Asjö
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

View more
  40 in total

1.  In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.

Authors:  Benoit Visseaux; Charlotte Charpentier; Margarita Hurtado-Nedelec; Alexandre Storto; Romain Antoine; Gilles Peytavin; Florence Damond; Sophie Matheron; Françoise Brun-Vézinet; Diane Descamps
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Modest human immunodeficiency virus coreceptor function of CXCR3 is strongly enhanced by mimicking the CXCR4 ligand binding pocket in the CXCR3 receptor.

Authors:  Sigrid Hatse; Dana Huskens; Katrien Princen; Kurt Vermeire; Gary J Bridger; Erik De Clercq; Mette M Rosenkilde; Thue W Schwartz; Dominique Schols
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

Review 3.  Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors:  Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

4.  Simian immunodeficiency viruses of diverse origin can use CXCR4 as a coreceptor for entry into human cells.

Authors:  S M Owen; S Masciotra; F Novembre; J Yee; W M Switzer; M Ostyula; R B Lal
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro.

Authors:  Y J Zhang; T Dragic; Y Cao; L Kostrikis; D S Kwon; D R Littman; V N KewalRamani; J P Moore
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

6.  In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.

Authors:  Sherie Masse; Xiaozhi Lu; Tatyana Dekhtyar; Liangjun Lu; Gennadiy Koev; Feng Gao; Hongmei Mo; Dale Kempf; Barry Bernstein; George J Hanna; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

7.  Adaptation to the interferon-induced antiviral state by human and simian immunodeficiency viruses.

Authors:  Julia Bitzegeio; Marissa Sampias; Paul D Bieniasz; Theodora Hatziioannou
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

8.  Access of HIV-2 to CD169-dependent dendritic cell-mediated trans infection pathway is attenuated.

Authors:  Suzanne D G Kijewski; Hisashi Akiyama; Amin Feizpour; Caitlin M Miller; Nora-Guadalupe P Ramirez; Björn M Reinhard; Suryaram Gummuluru
Journal:  Virology       Date:  2016-08-11       Impact factor: 3.616

9.  Detection of simian immunodeficiency virus in diverse species and of human immunodeficiency virus Type 2 by using consensus primers within the pol region.

Authors:  Silvina Masciotra; Chunfu Yang; Danuta Pieniazek; Chanda Thomas; Sherry M Owen; Harold M McClure; Renu B Lal
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

10.  V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1.

Authors:  S Y Chan; R F Speck; C Power; S L Gaffen; B Chesebro; M A Goldsmith
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.